Europe
ImmunoQure AG, a biotechnology company focused on the development of autoantibodies as therapeutics to treat human diseases and Memo Therapeutics AG, a biotechnology company focused on the discovery and development of therapeutic antibodies from cognate paired antibody libraries today announced the establishment of a collaborative partnership to create libraries from APS-1 memory B cells.
Motif Bio plc announced that the Company has signed an agreement with the Walter Reed Army Institute of Research to conduct pre-clinical testing to evaluate novel combinations with iclaprim to improve safety and efficacy administered by a novel enhanced aerosol technology.
On Thursday, FTC staff reviewing Roche’s $4.8 billion bid for Spark gave the deal a thumbs up after reviewing the potential merger.
In its announcement on Thursday, the FDA said its preliminary tests of alternative antacid treatments such as Pepcid (famotidine), Tagamet (cimetidine), Nexium (esomeprazole), Prevacid (lansoprazole), and Prilosec (omeprazole) currently show no NDMA at this time based on testing.
Innovative approach for hard-to-treat cancers being developed at the Cancer Research UK Beatson Institute
CELLINK publishes the quarterly report for the period 1st of June 2019 – 31st of August 2019 and for the full year of operations 2018-2019.
BioArctic and Eisai presented new data regarding BAN2401 at the Alzheimer’s Association International Conference® (AAIC®) in July that confirmed BAN2401’s unique characteristics and was consistent with previously presented results
The World Federation of Neurology is joining forces with the World Health Organization to create global standards of neurological care.
First academic bridge partnership in Israel aims to translate early-stage research from the Hebrew University (“HU”) of jerusalem into industrial drug development projects
In the framework of the collaboration, Genedata delivers fully validated cloud-based enterprise solution for integration, management and analysis of clinical, biomarker, NGS, and digital pathology data from public and clinical studies to enable AI-driven development of next generation therapeutics.
PRESS RELEASES